Get started

Pharmaceuticals

GlaxoSmithKline ShortShort from $42.01. - Market Cap: $102B - Beta: 0.83 - P/B: 20.42 - GSK’s consumer healthcare segment sales were down in 2017 due to a slowdown in global growth of its key consumer categories. - They have also faced pricing pressure from competition and slow down in emerging markets. Although GSK have several candidates in different stages of development, the company has been set back on numerous occasions by the regulators. The largest setbacks in the past few quarters include the phase 3 data on chronic coronary heart disease, Duchenne muscular dystrophy candidate, kydrisa failing to meet the primary end point in a phase 3 study. - The company phases massive competition from small start-ups to large pharmaceutical corporations. There consumer healthcare segment faces competition from big companies like Johnson & Johnson, Colgate Palmolive, Procter & Gamble and Pfizer. - Advair, one of GSK’s largest revenue providers is facing intense competition in the asthma and COPD market from AstraZeneca and Merck respiratory drugs. NeroTree Capital rates GlaxoSmithKline PLC as a SELL with a price target of $38.
NYSE:GSKShort
by UnknownUnicorn2415222
1
$TEVA - Berkshire breakout? Disclaimer, TEVA is in a very bad financial position, with dwindling cashflows and large debt. Buffet has always been the king of "value investing", hence why a position in Teva isn't surprising from him - it's most likely that he sees the company as severely undervalued and is entering into stages of repair. Buffet's new position in Teva was widely publicised this week: fortune.com markets.businessinsider.com finance.yahoo.com Just after Buffet disclosed the position, Teva announced the U.S. release of the QVAR Redihaler Inhalation Aerosol. www.streetinsider.com -new form of asthma inhalation treatment -breath actuated I don't think this is too important. I'd much rather to follow his other position into AAPL rather than TEVA
NYSE:TEVA
by UnknownUnicorn2421992
1
Dechra Pharmaceuticals Fake-BreakoutLast post: June 3rd. See chart . Review: Price was approaching the resistance level. Update: Since the last post, price broke above the resistance level but has failed to stay there and has now fallen back below that level. The breakout was a fake breakout. Conclusion: We need price to break the resistance level again and stay above it before looking for trading opportunities. Any comments or questions, do not hesitate to leave them below. Give us the thumbs up if you share our sentiments! Sublime Trading
DLong
by Sublime_Trading
Dechra Pharmaceuticals Looks Set To Breakout SoonLast post: Feb 28th. See chart . Review: Price had broken a resistance level with a strong move to the upside. Update: Price continued to trend higher but is now in a period of consolidation. Conclusion: We will be waiting for a breakout of the resistance of the consolidation zone before considering a trade. Any comments or questions, do not hesitate to leave them below. Give us the thumbs up if you share our sentiments! Sublime Trading
DLong
by Sublime_Trading
Small Pharma Big Backers and Partners - LONG SNG (Synairgen)Prudent Drug Discovery Company Low market cap ( appox £13m at time of writing ). Issues shares very rarely ( last placing nearly four years ago ). Has material interest in its work from larger partners ( Pharmaxis ). Sold interest in LOXL2 programme for £5m to Pharmaxis in December. Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest across all fibrotic indications at circa 17% of all partnering proceeds. Potential of drug appears across multiple uses now ( not just lung-related ) and indications from Pharmaxis looking very good. Recent interviews from Pharmaxis management suggest a good chance of a deal with major pharma in H2. Low free float in the stock ( 60% in hands of major shareholders ). Major funds holding ( Woodford Investment Management and Lansdowne Partners ). High profile investors holding stakes ( Richard Griffiths and Leonard Licht ). These high profile investors have been raising, rather than reducing their stakes in the company, periodically. For a risky smallcap biotech stock it appears well placed to survive and thrive, regardless of the short term success of a sale/licencing deal of LOXL2 by Pharmaxis, making it considerably less risky than most biotech stocks in the long term. However, the indications and noises being made about LOXL2 by Pharmaxis are looking as positive as you could hope for, and backed up by them putting their money where their mouth is in the first place and increasing their stake for cash.
SLong
by richthenewbie
3
Teva is now a buyAfter a couple of years where price has persistently followed the downtrend, last week Teva broke up such dynamic hreshold. Price has confirmed such trendline with a hammer 3 days ago at 17.04 dollars. Moreover we have the cross on the daily pattern between MA 50 and MA 200 turning to bullish set-up. Q1 earnings has been released beating expectations. SAR is positive and supertrend recently turned into bullish conformation as well. Trump is due to talk about drug prices this week but I don't deem Teva will be harshly impacted, because of the type of business. On a daily basis the hammer of three days ago confirmed by two green candles bear witness to a short term reversal. TP around 21.50/21.80
NYSE:TEVALong
by TRADOMICS_
MYL a buy opportunityAfter the breach of the multiyears downtrend prices have jumped till 47.68 dollars. We have seen a retracement according to the uptrend in progress. The price level around 39-40 is a stong support where a long can be setup. SL can be put a bit lower just underneath the MA 200 at 38 dollars. MA 200 is still under MA 50 and MACD is crossing over for a bullish setup. On top of that, price has reacted promptly after the NASDAQ sell off the day before yesterday.
MLong
by TRADOMICS_
Shaping the Future - an analysis on GWPHGood Afternoon and welcome to an analysis on GWPH. Looking at the chart we can see that GWPH broke through the support line on 2/22 and is now testing it as the current Major Resistance line. We have fallen to the Major Support line on 3/2 and bounced back up to touch the resistance line again. We almost looked as though we were going to break into the resistance line however all indicators show we are heading back down, at least for the short time. Looking at the DMI the +DM and the -DM touched briefly on 3/9 but then like a magnet split away from each other. The ADX is still above a 25 (barely), but nevertheless it is still above the signal line showing we are in a strong trend, and that current trend has been bearish. Plus the RSI hit my projected downward line and turned to head back south helping to confirm we indeed could drop further. The MACD is relatively flat and has turned up but it is still below out signal line as well. From the looks of the chart at the moment we could definitely head back down to touch the support line again. A good entry point would be between $109 and $111 with placing a stop loss just below the support line to minimize loss. Since Sep. of 2016 we have been in a trading range from roughly $95 - $140. Currently we are on the lower end of that spectrum. My personal opinion, with more doors opening for the legalization of marijuana in different states in the US and in other countries, I believe this GWPH is a good long hold. They have an A+ team, and I believe they will shape the future of cannabis-based therapeutics. Happy Trading :) Much Love DustyPH *all comments are welcome* ***This information is not a recommendation to buy or sell***
GLong
by dustyPH
INSY Target $23 FDA Cannabidiol Fast trackFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes. “FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, a debilitating condition which currently does not have any approved products available,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “We plan to start the clinical development program for this promising therapy in late first quarter of 2018.” The most common known genetic cause of life-threatening obesity in children, Prader-Willi syndrome has a prevalence of approximately 1 in 15,000, according to the Prader-Willi Syndrome Association, occurring in males and females equally and in all races. “We are very encouraged by the FDA’s decision to put CBD for Prader-Willi on the Fast Track and believe it is good news for these young patients, their families and clinicians,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “This special regulatory designation represents a significant milestone in the company’s R&D program, which is focused on developing and delivering safe, effective and novel treatment options using cannabinoids and novel drug delivery technology for unmet medical needs.” About INSYS INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. Forward-Looking Statements This news release contains forward-looking statements including regarding (i) our belief that FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, (ii) our belief that Prader-Willi syndrome currently does not have any approved products available and that our proprietary CBD formulation has potential to be a viable treatment option and (iii) our plan to start the clinical development program for this promising therapy in late first quarter of 2018. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
ILong
by StockPicksNYC98
VRX toward the first TPVRX yesterday has reached the first TP around 24.3/24.5 according to what happened some years ago. I expect some resistence here. if such hurdle will be step over, I expect another resistence at 26/27. This because some investors will take profit from the rally began in November: From 11 dollars to 19 (the neckline) 8 dollars of difference. 8+19= 27. Third TP is around 32/33 dollars. In the meantime Valeant will present at JP Morgan healthcare conference on the 10 jan, whilst fresch data on bussiness activity will be rolled out on 22 of febraury.
VLong
by TRADOMICS_
Finding the upcoming support zone and the right time to sell/buyAcadia Pharmaceuticals has shown a downward swing during the past 2 business days or so. Before that it was on a very big run, which on my opinion was due to the high demand and the low buy/sell price. It will soon find support around the 32.67 up to the 38 zone (see the purple channel) based on the past downswing which i just stated. In the very near future it will also go on an run as big as the last one or maybe a little slower, but it will fall out again. In my opinion it would be better to buy soon, sell some when it breaks the channel and then sell more when it reaches the climax of the channel.
NASDAQ:ACAD
by AlbanSako
Teva strong resistence at 19.33, yet not a buyDespite the recent company's efforts to reduce its debit, from a technical point of view, I would be neutral with Teva until we will see a cross-over between slow 200d and fast 50d moving average on a daily chart pattern. For those who are aggressives MACD is still positive but keep in mind the resistence at 19.33 first and 20 after. Exhaustion gap betweeen 16 and 18 has been filled. Personally I see such movement as a prize for what the new CEO has done to reduce the impact of debit in short and mid term. Still 2018 will be critical to conferm that what has been undertaken is going toward in the right direction.
NYSE:TEVA
by TRADOMICS_